Browsing Tag
Innovent Biologics
35 posts
China NMPA accepts NDA for Innovent and HUTCHMED’s sintilimab-fruquintinib combo in advanced renal cell carcinoma
Innovent Biologics (HKEX: 01801) and HUTCHMED (NASDAQ: HCM) secure NDA acceptance in China for sintilimab-fruquintinib in RCC, signaling oncology market shift.
Phase 3 trials to watch in 2025: Why this year matters for biotech investors
Explore the top Phase 3 trials of 2025 from Eli Lilly, GSK, and Innovent Biologics — including pipeline impact, investor sentiment, and regulatory milestones.
Innovent Biologics advances Phase 2 study of efdamrofusp alfa in diabetic macular edema amid global push for longer-acting therapies
Innovent launches Phase 2 trial of its anti-VEGF-complement fusion protein IBI302 to rival Faricimab in treating diabetic macular edema.
Innovent’s IBI363 gains NMPA breakthrough therapy designation, boosting regulatory momentum
Innovent’s IBI363 secures NMPA breakthrough therapy designation for melanoma. Discover its clinical potential, investment outlook, and global impact.
Innovent Biologics advances IBI354 into Phase 3 trial for HER2-expressing platinum-resistant ovarian cancer
Discover how Innovent Biologics is advancing IBI354, a novel HER2-targeted therapy, into Phase 3 trials to transform ovarian cancer treatment.
Innovent secures NMPA approval for SYCUME, China’s first IGF-1R antibody for thyroid eye disease
Innovent Biologics has received approval from China’s National Medical Products Administration (NMPA) for SYCUME (teprotumumab N01), marking a…
Innovent begins IBI363 pivotal study in melanoma immunotherapy
Innovent Biologics, Inc. (HKEX: 01801), a global biopharmaceutical company specializing in innovative oncology therapies, has dosed the first…
Innovent Biologics and Roche partner to advance DLL3 antibody drug conjugate
Innovent Biologics, Inc., a biopharmaceutical company, has entered a strategic global licensing agreement with Roche to propel the…
Innovent, Hutchmed announce conditional approval for cancer drug combination therapy
Innovent Biologics and Hutchmed (china) limited have received conditional nmpa approval for the combination therapy of tyvyt (sintilimab…
Innovent Biologics, IASO Bio strengthen collaboration with equity investment and licensing deal
Innovent Biologics, Inc. (HKEX: 01801), a globally recognized biopharmaceutical company, and IASO Biotechnology, a leader in innovative cell…